Impact of bone-marrow-derived mesenchymal stem cells on adriamycin-induced chronic nephropathy

Background Renal damage caused by drug toxicity is becoming more and more common in clinic. How to avoid and treat kidney damage caused by drug toxicity is essential to maintain patient health and reduce social economic burden. In this study, we performed a meta-analysis to assess the nephroprotective effect of mesenchymal stem cells (MSCs) in therapy of kidney disease induced by toxicant. Methods Cochrane Library, Embase, ISI Web of Science and PubMed databases were searched up to Dec 31, 2019 to identify the studies and extract the data to assess the efficacy of MSCs for kidney disease induced by toxicant using Cochrane Review Manager Version 5.3. Results 27 studies were eligible and recruited for this meta-analysis. The results showed that the difference of Scr between MSCs treatment group and control group was notable for 2 days, 4 days, 5 days, 6-8 days, 10-15 days, ≥42 days (2 days: WMD =-0.88, 95%CI: -1.34, -0.42, P=0.0002; 4 days: WMD=-0.69, 95%CI: -0.99, -0.39, P<0.00001; 5 days: WMD=-0.46, 95%CI: -0.67, -0.25, P<0.0001; 6-8 days: WMD=-0.51, 95%CI: -0.79, -0.22, P=0.0005; 10-15 days: WMD =-0.38, 95%CI: -0.56, -0.20, P<0.0001; ≥42 days: WMD =-0.22, 95%CI: -0.39, -0.06, P=0.007). Furthermore, the difference of BUN between MSCs treatment group and control group was notable for 2-3 days, 4-5 days, 6-8 days, ≥28 days. The results also indicated that MSCs treatment can alleviate the inflammatory cells, necrotic tubule, regenerative tubules, renal interstitial fibrosis in kidney disease induced by toxicant. Conclusion: MSCs might be a promising therapeutic agent for kidney disease induced by toxicant.

show abstract

“…In this meta-analysis, four studies [16,18,22,26] were included for the assessment of MDA, four [16,18,22,26] for GSH, three [10,16,22] Table 2).…”

Section: Oxidative Stressmentioning

confidence: 99%

“…Four studies [16,23,26,34] for inflammatory cells, two studies [16,26] for necrotic tubule, two studies [16,26] for regenerative tubules and three studies [16,26,34] Table 2).…”

Section: Assessment Of Renal Pathologymentioning

confidence: 99%

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Zhou

Lin

Liao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In this meta-analysis, four studies [16,18,22,26] were included for the assessment of MDA, four [16,18,22,26] for GSH, three [10,16,22] for SOD. The results indicated that the difference between MSCs treatment group and control group was notable for MDA, GSH, SOD (MDA: WMD=-17.21, 95%CI: -20.38, -14.04, P < 0.00001; GSH: WMD = 4.62, 95%CI: 2.74, 6.50, P < 0.00001; SOD: WMD = 5.42, 95%CI: 2.92, 7.93, P < 0.0001; Table 2).…”

Section: Oxidative Stressmentioning

confidence: 99%

“…Four studies [16,23,26,34] for in ammatory cells, two studies [16,26] for necrotic tubule, two studies [16,26] for regenerative tubules and three studies [16,26,34] Table 2).…”

Section: Assessment Of Renal Pathologymentioning

confidence: 99%

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Zhou

Lin

Liao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Renal damage caused by drug toxicity is becoming more and more common in clinic. How to avoid and treat kidney damage caused by drug toxicity is essential to maintain patient health and reduce social economic burden. In this study, we performed a meta-analysis to assess the nephroprotective effect of mesenchymal stem cells (MSCs) in therapy of kidney disease induced by toxicant. Methods Cochrane Library, Embase, ISI Web of Science and PubMed databases were searched up to Dec 31, 2019 to identify the studies and extract the data to assess the efficacy of MSCs for kidney disease induced by toxicant using Cochrane Review Manager Version 5.3. Results 27 studies were eligible and recruited for this meta-analysis. The results showed that the difference of Scr between MSCs treatment group and control group was notable for 2 days, 4 days, 5 days, 6–8 days, 10–15 days, ≥ 42 days (2 days: WMD =-0.88, 95%CI: -1.34, -0.42, P = 0.0002; 4 days: WMD=-0.69, 95%CI: -0.99, -0.39, P < 0.00001; 5 days: WMD=-0.46, 95%CI: -0.67, -0.25, P < 0.0001; 6–8 days: WMD=-0.51, 95%CI: -0.79, -0.22, P = 0.0005; 10–15 days: WMD =-0.38, 95%CI: -0.56, -0.20, P < 0.0001; ≥42 days: WMD =-0.22, 95%CI: -0.39, -0.06, P = 0.007). Furthermore, the difference of BUN between MSCs treatment group and control group was notable for 2–3 days, 4–5 days, 6–8 days, ≥ 28 days. The results also indicated that MSCs treatment can alleviate the inflammatory cells, necrotic tubule, regenerative tubules, renal interstitial fibrosis in kidney disease induced by toxicant. Conclusion MSCs might be a promising therapeutic agent for kidney disease induced by toxicant.

show abstract

“…Sections (4-μm-thick) cut from 10% formalin-fixed, paraffin-embedded kidney samples were stained with Hematoxylin and Eosin (H&E) and Masson Trichrome staining, for evaluation of renal glomerular damage, tubulo-interstitial damage (Cao et al, 2000) and degree of fibrosis (Sarhan et al, 2014).…”

Section: Renal Histopathological Examinationmentioning

confidence: 99%

Valsartan reduces NOX4 expression and halts diabetic nephropathy in streptozotocin induced diabetic rat model

et al. 2019

View full text Add to dashboard Cite

Background: Diabetic nephropathy is the leading cause of kidney failure worldwide. NADPH oxidase 4 (NOX4) is an obvious cause for reactive oxygen species production in the kidney mainly via renin-angiotensin system. High reactive oxygen species results in kidney damage through direct effect or through activation of other pathways such as the extracellular regulated kinase (ERK) signaling pathway.Aim: The present study was constructed to investigate the effect of angiotensin II receptor blocker, valsartan, on NOX4, ERK1/2expression, and malondialdehyde level as well as their effects on the progression of diabetic nephropathy in type 1 diabetic rat model. Methods:The experimental rats were divided into three groups: group I control healthy untreated rats, group II streptozotocin-induced diabetic rats, and group III valsartan treated streptozotocin-induced diabetic rats.Results: Valsartan showed significantly decreased NOX4 and ERK1/2 mRNA, NOX4 and pERK1/2 protein concentration, and oxidative stress as evidenced by low malondialdehyde concentration in treated diabetic rats. Valsartan attenuates albuminuria, improve overall kidney function parameters, and pathological changes compared to diabetic non-treated rats.Conclusion: Valsartan treatment impedes renal damage and improve kidney function in treated diabetic nephropathy rats. The beneficial effect of valsartan was mediated through decrease oxidative stress via downregulation of NOX4 and ERK1/2 and decreased reactive oxygen species production.

show abstract

Impact of bone-marrow-derived mesenchymal stem cells on adriamycin-induced chronic nephropathy

Abstract: administration of BM-MSCs during induction of ADR nephropathy provides partial protection, which could be due to improvements in the levels of of endogenous antioxidants, reduction of apoptosis, and maintenance of the integrity of the glomerular membrane.

Cited by 19 publications

References 42 publications

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Valsartan reduces NOX4 expression and halts diabetic nephropathy in streptozotocin induced diabetic rat model

Contact Info

Product

Resources

About